Diakonos Oncology's dendritic cell vaccine shows promise despite development hurdles

Cellipoint Bioservices signed an agreement with Diakonos Oncology in October 2023 for the development and manufacturing of DOC1021, an autologous dendritic cell (DC) vaccine.

Related Keywords

United Kingdom ,Germany ,Jasminemay Barcelon ,Dendreon Provenge ,Biotherapeutic Dcvax ,Healthcare Products Regulatory Agency ,Diakonos Oncology ,Fast Track Designation ,Marketing Authorization Application ,Aivita Biomedical ,Immunomic Therapeutic ,Bio Developments ,Markets Amp Regulations ,Pipelines ,Emerging Markets ,Ncology ,Dancer ,Clinical Trials ,Vaccine ,